

Supplementary Table 2. Analysis of association between expression of SSTR2 and EGFR and clinicopathological features of NPC (491)

Clinicopathological features	SSTR2			EGFR			SSTR2/EGFR			SSTR2/EGFR		
	L (%)	H (%)	P-Value	L (%)	H (%)	P-Value	SSTR2/EGFR (%) [#]	Others (%)	P-Value	SSTR2/EGFR(%) ^{&}	Others(%)	P-Value
Gender			0.044*			0.965			0.167			0.399
Male (n=349)	202(57.9)	147(42.1)		99(28.4)	250(71.6)		129(37.0)	220(63.0)		268(76.8)	81(23.2)	
Female (n=142)	68(47.9)	74(52.1)		40(28.2)	102(71.8)		62(43.7)	80(56.3)		114(80.3)	28(19.7)	
Age			0.899			0.738			0.898			0.951
≤45 (n=143)	78(54.5)	65(45.5)		42(29.4)	101(70.6)		55(38.5)	88(61.5)		111(77.6)	32(22.4)	
>45 (n=348)	192(55.2)	156(44.8)		97(27.9)	251(72.1)		136(39.1)	212(60.9)		271(77.9)	77(22.1)	
T stage			0.216			0.666			0.293			0.474
T1 and T2 (n=215)	125(58.1)	90(41.9)		63(29.3)	152(70.7)		78(36.3)	137(63.7)		164(76.3)	51(23.7)	
T3 and T4(n=276)	145(52.5)	131(47.5)		76(27.5)	200(72.5)		113(40.9)	163(59.1)		218(79.0)	58(21.0)	
N stage			0.249			0.857			0.654			0.293
N0 (n=58)	36(62.1)	22(37.9)		17(29.3)	41(70.7)		21(36.2)	37(63.8)		42(72.4)	16(27.6)	
N1/2/3(n=433)	234(54.0)	199(46.0)		122(28.2)	311(71.8)		170(39.3)	263(60.7)		340(78.5)	93(21.5)	
M stage			0.250			0.576			0.206			0.618
M0 (n=454)	253(55.7)	201(44.3)		130(28.6)	324(71.4)		173(38.1)	281(61.9)		352(77.5)	102(22.5)	
M1 (n=37)	17(45.9)	20(54.1)		9(24.3)	28(75.7)		18(48.6)	19(51.4)		30(81.1)	25(18.9)	
Disease Progression			0.007**			0.016*			0.003**			0.020*
No progress (n=358)	210(58.7)	148(41.3)		112(31.3)	246(68.7)		125(34.9)	233(65.1)		269(75.1)	89(24.9)	
Progress (n=133)	60(45.1)	73(54.9)		27(20.3)	106(79.7)		66(49.6)	67(50.4)		113(85.0)	20(15.0)	

Abbreviations: H, high expression; L, low expression. SSTR2, Somatostatin receptor 2; EGFR, epidermal growth factor receptor; CR, chemo-radiotherapy. [#]: high co-expression of SSTR2 and EGFR; [&]: EGFR/SSTR2 anyone high expression

Note: Chi-square test, *P<0.05, **P<0.001